



Merck Limited- Dr. A. B. Rd, Worli, -400 018 Mumbai

Date January 30, 2013

Division/Dept.
Care of
Phone
Fax
E-mail

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Mumbai - 400051

~~Your letter~~ Bombay Stock Exchange Ltd
~~Your ref~~ 1st Floor, Rotunda Building,
Dalal Street, Fort,
Mumbai - 400 001

Dear Sir,

Sub: Declaration of dividend and announcement of audited financial results as per clause 41 of Listing Agreement and notice of Annual General Meeting.

With reference to the above we are enclosing herewith the audited financial results for the quarter and year ended December 31, 2012 as approved by the Board of Directors of the Company at its Meeting held today on January 30, 2013.

The Audited Financial Results shall be published in the newspapers as stipulated under the listing agreement.

The Board has recommended dividend at the rate of Rs. 2.50/- (Rupees two and fifty paisa) per equity share of Rs. 10/- each.

We wish to inform you that the 46th Annual General Meeting of the Company will be held on Friday, March 15, 2013, at 3 pm at Mayfair Banquets - South Hall 254-C, Dr. Annie Besant Road, Worli, Mumbai-30.

In terms of Clause 16 of the Listing Agreement, we hereby inform you that the Register of Members and the Share Transfer Books of the Company will remain closed from March 09, 2013 to March 15, 2013 (both days inclusive) for the purpose of payment of dividend for the year ended December 31, 2012 as may be declared at the forthcoming Annual General Meeting.

Please acknowledge the receipt of the same.

Thanking you,

Yours faithfully,

For Merck Limited

Vikas Gupta

General Counsel & Company Secretary

Merck Limited

Shiv Sagar Estate 'A',
Dr. A. B. Road, Worli, 400 018 Mumbai, India.
Phone 91 22 66609000
Fax 91 22 24950307
www.merck.co.in

MERCK LIMITED
Regd. Office: Shivsagar Estate 'A', Dr. Annie Besant Road, Worli, Mumbai - 400018
AUDITED FINANCIAL RESULTS FOR YEAR ENDED 31ST DECEMBER, 2012

(Rs. in Lakhs)						(Rs. in Lakhs)					
Particulars	3 months ended 31/12/2012	Preceding 3 months ended 30/09/2012	Corresponding 3 months ended 31/12/2011 in the previous year	Year to date figures for the current year ended 31/12/2012	Previous year ended 31/12/2011	Segment Wise Revenue, Result and Capital Employed					
	Audited	Unaudited	Audited	Audited	Audited	Particulars	3 months ended 31/12/2012 Audited	Preceding 3 months ended 30/09/2012 Unaudited	Corresponding 3 months ended 31/12/2011 in the previous year Audited	Year to date figures for the current year ended 31/12/2012 Audited	Previous year ended 31/12/2011 Audited
1. Income from operations						1. Segment Revenue					
a) Net Sales/Income from operations (Net of excise duty)	16,117.94	18,120.95	12,656.71	66,807.05	55,757.08	a) Pharmaceuticals	10,912.35	12,685.30	8,469.38	45,733.52	40,488.59
b) Other operating income	638.70	678.90	865.85	2,920.90	3,198.14	b) Chemicals	6,277.68	6,508.53	5,466.87	24,639.33	19,737.24
Total Income from operations (net)	16,756.64	18,799.85	13,522.56	68,727.95	58,955.22	Total	17,190.03	19,193.83	13,936.25	70,372.85	60,225.83
2. Expenses						Less : Inter segment revenue	433.39	393.98	413.69	1,644.90	1,270.61
a) Cost of materials consumed	4,352.78	4,815.51	3,493.63	17,943.63	16,953.81	Net Sales and Other Operating Income	16,756.64	18,799.85	13,522.56	68,727.95	58,955.22
b) Purchases of stock-in-trade	3,068.71	2,933.33	3,732.11	11,608.69	11,318.40	2. Segment Results (Profit before Tax and Interest from each segment)					
c) Changes in inventories of finished goods, work-in-progress and stock in trade	(126.75)	498.13	(1,135.88)	349.14	(3,994.60)	a) Pharmaceuticals	1,586.01	2,523.10	(131.60)	6,554.67	4,008.96
d) Employee benefits expense	1,747.57	2,191.45	2,086.51	8,530.07	8,110.19	b) Chemicals (Refer Note 3)	763.03	861.58	1,617.70	3,199.03	3,905.63
e) Depreciation and amortisation expense	240.42	230.22	330.92	889.77	795.34	Total	2,349.04	3,384.68	1,486.10	9,753.70	7,914.59
f) Other expenses	5,190.00	4,760.89	4,973.46	19,747.21	19,330.95	Less : Other un-allocable expenditure net off un-allocable Income	(533.10)	(507.86)	(404.62)	(1,925.30)	(1,644.00)
Total expenses	14,462.73	15,429.53	13,480.77	69,068.51	52,514.09	Total Profit before Tax	2,882.14	3,892.54	1,890.72	11,879.00	9,558.59
3. Profit from operations before other income, finance costs and exceptional items (1-2)	2,293.91	3,370.32	41.79	9,659.44	6,441.13	3. Capital Employed					
4. Other Income	588.23	522.22	420.93	2,019.66	1,689.46	a) Pharmaceuticals	7,864.43	9,132.14	8,568.30	7,864.43	8,568.30
5. Profit from ordinary activities before finance costs and exceptional items (3+4)	2,882.14	3,892.54	462.72	11,679.00	8,130.59	b) Chemicals	13,946.60	13,325.41	11,448.00	13,946.60	11,448.00
6. Finance Cost	-	-	-	-	-	c) Unallocated	26,555.10	24,385.61	20,992.00	26,555.10	20,992.00
7. Profit from ordinary activities before finance costs and exceptional items (5-6)	2,882.14	3,892.54	462.72	11,679.00	8,130.59	Total	48,366.13	46,843.16	41,008.30	48,366.13	41,008.30
8. Exceptional items (Refer Note 3)	-	-	1,428.00	-	1,428.00	Statement of Assets and Liabilities					
9. Profit from ordinary activities before tax (7+8)	2,882.14	3,892.54	1,890.72	11,679.00	9,558.59	Particulars	As at Current year year end 31.12.2012		As at Previous year end 31.12.2011		
10. Tax expense *	876.86	1,312.37	624.28	3,838.86	3,190.57	A EQUITY AND LIABILITIES					
11. Net Profit from Ordinary Activities after tax (9-10)	2,005.28	2,580.17	1,266.44	7,840.14	6,368.02	1 Shareholders' Funds					
12. Extraordinary items (net of tax expense)	-	-	-	-	-	(a) Share capital					
13. Net Profit for the period (11±12)	2,005.28	2,580.17	1,266.44	7,840.14	6,368.02	(b) Reserves and surplus					
14. Paid-up equity share capital (Face Value Rs 10/-)	1,659.94	1,659.94	1,659.94	1,659.94	1,659.94	Sub-total-Shareholders' funds					
15. Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	46,706.19	39,348.36	2 Non-current liabilities					
16.i Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):						(a) Deferred tax liabilities (net)					
(a) Basic	12.08	15.54	7.63	47.23	38.36	(b) Long-term provisions					
(b) Diluted	12.08	15.54	7.63	47.23	38.36	Sub-total-Non-current liabilities					
16.ii Earnings per share (after extraordinary items) (of Rs 10/- each) (not annualised):						3 Current liabilities					
(a) Basic	12.08	15.54	7.63	47.23	38.36	(a) Trade payables					
(b) Diluted	12.08	15.54	7.63	47.23	38.36	(b) Other current liabilities					
						(c) Short-term provisions					
						Sub-total-Current liabilities					
						TOTAL - EQUITY AND LIABILITIES					
						59,427.48 49,962.11					
						B ASSETS					
						1 Non-current assets					
						(a) Fixed assets					
						(b) Long-term loans and advances					
						Sub-total - Non-current assets					
						2 Current assets					
						(a) Current investments					
						(b) Inventories					
						(c) Trade receivables					
						(d) Cash and cash equivalents					
						(e) Short-term loans and advances					
						(f) Other current assets					
						Sub-total - Current assets					
						45,849.71 37,935.43					
						TOTAL - ASSETS					
						59,427.48 49,962.11					
						</					

Notes :-

- The above results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 30th January, 2013. The statutory auditors have expressed an unqualified opinion. The audit report has been filed with stock exchange and is available on the company's website.
- Figures for the previous quarter/year have been re-grouped/re-arranged wherever necessary.
- During the previous year ended 31st December 2011, the Company had reversed provision for impairment loss of Rs.1.428 Lakhs on a cash generating unit. This has been considered in the results of the Chemicals segment.
- The figures of last quarter are the balancing figures between audited figures in respect of full financial year and the published year to date figures upto the third quarter of the current financial year and previous financial year.
- The Board of Directors at its meeting held on 30th January, 2013 recommended a final dividend of Rs. 2.50 per share.

Place : Mumbai
Date : 30th January, 2013
Please visit us at our website www.merck.co.in

For MERCK LIMITED

DR. C. BOEDECKER
MANAGING DIRECTOR